Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

Defective epithelial barrier responsible for up to two billion chronic diseases

Defective epithelial barrier responsible for up to two billion chronic diseases

Targeted Therapies Alliance provides new information, resources about the rheumatoid arthritis journey

Targeted Therapies Alliance provides new information, resources about the rheumatoid arthritis journey

People of color with rheumatic disease have worse COVID-19 outcomes

People of color with rheumatic disease have worse COVID-19 outcomes

AI enables accurate detection of radiographic sacroiliitis in people with axial spondyloarthritis

AI enables accurate detection of radiographic sacroiliitis in people with axial spondyloarthritis

Study: Female patients with ankylosing spondylitis can still have children

Study: Female patients with ankylosing spondylitis can still have children

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Updated recommendations for treatment of patients with axial spondyloarthritis released

Updated recommendations for treatment of patients with axial spondyloarthritis released

IMAS survey reveals 74% of people living with axial spondyloarthritis struggle to find a job

IMAS survey reveals 74% of people living with axial spondyloarthritis struggle to find a job

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

MSU researchers move one step closer to solving arthritic disease in teenagers

MSU researchers move one step closer to solving arthritic disease in teenagers

Researchers discover new protein that controls level of inflammation-inducing molecule

Researchers discover new protein that controls level of inflammation-inducing molecule

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Price check on drug ads: Would revealing costs help patients control spending?

Price check on drug ads: Would revealing costs help patients control spending?